Home » Stocks » MRTX

Mirati Therapeutics, Inc. (MRTX)

Stock Price: $157.13 USD -2.20 (-1.38%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 8.08B
Revenue (ttm) 13.13M
Net Income (ttm) -406.96M
Shares Out 50.78M
EPS (ttm) -8.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $157.13
Previous Close $159.33
Change ($) -2.20
Change (%) -1.38%
Day's Open 159.60
Day's Range 153.83 - 159.77
Day's Volume 272,985
52-Week Range 115.44 - 249.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.

3 weeks ago - Zacks Investment Research

The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the KRAS-G12C mutation. The decision was ba...

4 weeks ago - Benzinga

SAN DIEGO, June 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has grante...

4 weeks ago - PRNewsWire

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Global He...

1 month ago - PRNewsWire

SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688...

Other stocks mentioned: ZLAB
1 month ago - PRNewsWire

QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.

Other stocks mentioned: QGEN
1 month ago - Zacks Investment Research

With the trading day about halfway over, the markets were all over the place. The Nasdaq took a beating yet again, with the index down close to 1.7%.

Other stocks mentioned: BYND, HOME, LYFT, RTX, MGI, TFC, VIAC
2 months ago - 24/7 Wall Street

SAN DIEGO, May 6, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2021 and recent cor...

2 months ago - PRNewsWire

Mirati Therapeutics (MRTX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

2 months ago - Zacks Investment Research

SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational syn...

3 months ago - PRNewsWire

Revolution Medicines' leading compound is shaping up to be a platform in a pill.

Other stocks mentioned: AZN, MRK, RHHBY, RVMD, SNY
3 months ago - The Motley Fool

SAN DIEGO, March 31, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director,...

3 months ago - PRNewsWire

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...

Other stocks mentioned: DNLI, FATE, MRNA, NVAX, SGEN, ZLAB
4 months ago - InvestorPlace

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: ARGX, BHVN, BMRN, NVO, NVS
4 months ago - InvestorPlace

SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synt...

4 months ago - PRNewsWire

SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, ...

4 months ago - PRNewsWire

SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences. Friday, February 26th ...

5 months ago - PRNewsWire

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim H...

5 months ago - PRNewsWire

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Fra...

6 months ago - PRNewsWire

Leveraging sound science and prudent cancer treatment, Mirati is growing robustly. The two lead drugs (sitravatinib and Adagrasib) are rapidly advancing for different cancer indications.

6 months ago - Seeking Alpha

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, DNLI, NVAX, SGEN, ZLAB
7 months ago - InvestorPlace

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Everco...

8 months ago - PRNewsWire

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual ...

8 months ago - PRNewsWire

SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2...

8 months ago - PRNewsWire

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in r...

8 months ago - Insider Monkey

SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common s...

8 months ago - PRNewsWire

Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the...

8 months ago - PRNewsWire

Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at about $205...

8 months ago - GuruFocus

Which one of these biotech stocks has a better chance to provide market-beating gains?

Other stocks mentioned: AMGN
8 months ago - The Motley Fool

SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its com...

8 months ago - PRNewsWire

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

The biotech's positive clinical results announced on Sunday prompted analysts to boost their price targets on the stock.

8 months ago - The Motley Fool

Tiny Mirati Therapeutics posted positive preliminary data on a colorectal and lung cancer drug therapy in competition with drug giant Amgen, sending MRTX stock soaring to an all-time high. The post Tiny...

8 months ago - Investors Business Daily

SAN DIEGO, Oct. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRAS selectiv...

8 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Mir...

9 months ago - Newsfile Corp

SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), the Company...

9 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.

9 months ago - Business Wire

Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation.

9 months ago - Seeking Alpha

LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.

9 months ago - Business Wire

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating...

10 months ago - PRNewsWire

INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a S...

10 months ago - Business Wire

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.

10 months ago - PRNewsWire

ANN ARBOR, Mich., Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc.

11 months ago - PRNewsWire

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.

11 months ago - PRNewsWire

ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor

11 months ago - GlobeNewsWire

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

About MRTX

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in precli... [Read more...]

Industry
Biotechnology
IPO Date
Jun 29, 2004
CEO
Charles Baum
Employees
199
Stock Exchange
NASDAQ
Ticker Symbol
MRTX
Full Company Profile

Financial Performance

In 2020, MRTX's revenue was $13.40 million, an increase of 301.74% compared to the previous year's $3.34 million. Losses were -$357.94 million, 67.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 227.78, which is an increase of 44.96% from the latest price.

Price Target
$227.78
(44.96% upside)
Analyst Consensus: Buy